

Kakei S, Lee J, Mitoma H, Tanaka H, Manto M, Hampe CS. (2019) "Contribution of the Cerebellum to Predictive Motor Control and Its Evaluation in Ataxic Patients." *Front. Hum. Neurosci.* 13:216.

Tanaka H, Ishikawa T, Kakei S. (2019) "Neural Evidence of the Cerebellum as a State Predictor." *Cerebellum*.18(3):349-371.

Tomatsu S, Ishikawa T, Tsunoda Y, Lee J, Hoffman DS, and Kakei S. (2016) "Information processing in the hemisphere of the cerebellar cortrex for motor control of wrist movement." *J. Neurophysiol.* 115:255-270.

Ishikawa T, Tomatsu S, Izawa J, and Kakei S. (2016) "The cerebrocerebellum:Could it be loci of forward models?" **Neurosci. Res.** 104:72-79.

Lee J, Kagamihara Y, and Kakei S. (2015) "A new method for functional evaluation of motor commands in patients with cerebellar ataxia."*PLoS One* 10:e0132983.

Ishikawa T, Tomatsu S, Tsunoda Y, Lee J, Hoffman DS, and Kakei S. (2014) "Releasing dentate nucleus cells from Purkinje cell inhibition generates outputs from the cerebrocerebellum." *PLoS One* 9:e108774 (pp.1-16).

Project Shinji Kakei Motor Disorders Project

From Neuron to Action and its Disorders

We try to understand how the brain controls our movements in the real world. We study the process of action generation at a single neuron level using animal models to understand how movements are processed in the brain. We also study actions of healthy people, as well as those with neurological disorders, such as cerebellar disorders, Parkinson's disease or strokes. We look for building-blocks of motor control with multidisciplinary approaches. Our tools include various neurophysiological recording techniques (single unit recording, electromyography (EMG) and electro-encephalography (EEG)), brain stimulation, neuroimaging, analysis of movement kinematics and a large-scale modeling. We have two long-term goals: 1) to understand the basic function of the motor structures of the brain including the cerebellum, the basal ganglia, and the motor cortex; and 2) to understand how our brain controls our movements on the basis of the findings in 1).

"Through our research, we are trying to understand the brain. The brain was first created to control movement and

extended to control higher brain functions."



"The brain mechanism for motor control must provide a basic framework to understand higher brain functions."

The brain is an assembly of neural networks.



Motor Disorders



Hot Topics of Our Research

Members Kyuengbo Min, Jongho Lee, Takahiro Ishikawa, Takeru Honda



Motor Disorders



Harada C, Kimura A, Guo X, Namekata K, and Harada T. (2019) "Recent advances in genetically modified animal models of glaucoma and their roles in drug repositioning." *Br. J. Ophthalmol.* 103:161–166.

Sano H, Namekata K, Kimura A, Shitara H, Guo X, Harada C, Mitamura Y, and Harada T. (2019) "Differential effects of N-acetylcysteine on retinal degeneration in two mouse models of normal tension glaucoma." *Cell Death Dis.* 10:75.

Kimura A, Namekata K, Guo X, Noro T, Harada C, and Harada T. (2015) "Valproic acid prevents NMDAinduced retinal ganglion cell death via stimulation of neuronal TrkB receptor signaling." **Am. J. Pathol.** 185:756-764.

Noro T, Namekata K, Kimura A, Guo X, Azuchi Y, Harada C, Nakano T, Tsuneoka H, and Harada T. (2015) "Spermidine promotes retinal ganglion cell survival and optic nerve regeneration in adult mice following optic nerve injury." *Cell Death Dis.* 6: e1720.

Harada C, Guo X, Namekata K, Kimura A, Nakamura K, Tanaka K, Parada LF, and Harada T. (2011) "Glia- and neuron-specific functions of TrkB signalling during retinal degeneration and regeneration." *Nature Commun.* 2: 189.

Guo X, Harada C, Namekata K, Matsuzawa A, Camps M, Ji H, Swinnen D, Jorand-Lebrun C, Muzerelle M, Vitte P, Ruckle T, Kimura A, Kohyama K, Matsumoto Y, Ichijo H, and Harada T. (2010) "Regulation of the severity of neuroinflammation and demyelination by TLR-ASK1-p38 pathway." *EMBO Mol. Med.* 2:504-515.

Harada T, Harada C, Nakamura K, Quah HA, Okumura A, Namekata K, Saeki T, Aihara M, Yoshida H, Mitani A, and Tanaka K. (2007) "The potential role of glutamate transporters in the pathogenesis normal tension glaucoma." *J. Clin. Invest.* 117:1763-1770.

Neurodegenerative Diseases

More than 1.6 million people in Japan are visually impaired, representing economic social losses estimated at more than 8 trillion yen. In the particular context of the increased penetration of Western lifestyles and an aging society, the increase in the number of patients with conditions such as glaucoma and diabetic retinopathy, which could be called "adult eye diseases," has become a major social issue. To achieve improved quality of life (QOL) for the visually impaired in an increasingly aging population, we seek to elucidate detailed pathogenic mechanisms and develop new therapies through the development of a model of intractable eye disease.

Project Takayuki Harada Visual Research Project

Elucidation of Pathology and Development of Therapeutic Strategies for Retinal

Our objectives

"We are focusing on elucidating the molecular mechanisms of neuroprotection and neuroregeneration, and our final goal is the prevention or treatment of blindness in retinal neurodegenerative disorders such as glaucoma and traumatic injury."



Our major aim

- To develop a neuroprotective retinal therapy using animal disease models
- To elucidate the mechanisms involved in the onset of optic neuritis
- To establish a method to promote regeneration of the optic nerve





Namekata K, Kimura A, Kawamura K, Harada C, Harada T. (2014) "Dock GEFs and their therapeutic potential: Neuroprotection and axon regeneration." **Prog. Retin. Eye Res.** 43: 1-16,

Namekata K, Harada C, Guo X, Kimura A, Kittaka D, Watanabe H, Harada T. (2012) "Dock3 stimulates axonal outgrowth via GSK-3β-mediated microtubule assembly."

J. Neurosci. 32: 264-274,

Namekata K, Harada C, Taya C, Guo X, Kimura H, Parada LF, Harada T. (2010) "Dock3 induces axonal outgrowth by stimulating membrane recruitment of the WAVE complex." *Proc. Natl. Acad.Sci. USA* 107: 7586-7591,

Senior Research Scientist Kazuhiko Namekata

Dock family proteins

The dedicator of cytokinesis (Dock) family is composed of atypical guanine exchange factors (GEFs) that induce actin polymerization. To date, 11 Dock family members have been identified. Dock3 is predominantly expressed in the central nervous system. In the growth cone, Dock3 induces actin polymerization by activating WASP family verprolin-homologous protein (WAVE) and modulates microtubule dynamics through inactivation of GSK-3 β , leading to axon elongation. In addition, Dock3 plays a role in protecting retinal ganglion cells from neurotoxicity and oxidative stress. Dock3 may be a therapeutic target for optic neuropathy including glaucoma.



Axonal regeneration was enhanced in Dock3 overexpressing mouse (Tg) (Arrow heads indicate regenerating axons)



Visual Research



Nakayama Y, Shimizu T, Matsuda C, Haraguchi M, Hayashi K, Bokuda K, Nagao M, Kawata A, Ishikawa-Takata K, Isozaki E. (2019) "Body weight variation predicts disease progression after invasive ventilation in amyotrophic lateral sclerosis." *Scientific Reports* volume 9, Article number: 12262

Shimizu T, Nakayama Y, Matsuda C, Haraguchi M, Bokuda K, Ishikawa-Takata K, Kawata A, Isozaki E. 2019 "Prognostic significance of body weight variation after diagnosis in ALS: a single-centre prospective cohort study." *Journal of Neurology* .266(6), 1412–1420

Matsuda C, Shimizu T, Nakayama Y, Haraguchi M. (2019) "Cough peak flow decline rate predicts survival in patients with amyotorophic lateral sclerosis" *Muscle & Nerve.* 59(2) 168-173.

Shimizu T, Bokuda K, Kimura H, Kamiyama T, Nakayama Y, Kawata A, Isozaki E, and Ugawa Y. (2018) "Sensory cortex hyperexcitability predicts short survival in amyotrophic lateral sclerosis." *Neurology* 1 ;90(18): e1578-e1587.

Nakayama Y, Shimizu T,Matsuda C, Mochizuki Y, Hayashi K,Nagao M, Kawata A, Isozaki E. (2018) "Non-Motor Manifestations in ALS Patients with Tracheostomy and invasive ventilation." *Muscle and Nerve.* 57(5):735-741.

Nakayama Y, Shimizu T, Mochizuki Y, Hayashi K, Matsuda C, Nagao M, Watabe K, Kawata A, Oyanagi K, Isozaki E, Nakano I. (2016) "Predictors of impaired communication in amyotrophic lateral sclerosis patients with tracheostomy invasive ventilation." *Amyotroph Lateral Scler Frontotemporal Degener.* 17(1-2):38-46



Project Leader Yuki Nakayama ALS Nursing Care Project

Improving the Quality Of Life of Patients with Amyotrophic Lateral Sclerosis



"Our mission is to establish the best practices for respiratory and communication management for ALS patients in a community-based setting. We have established a multidisciplinary research team to develop a Brain Machine Interface for ALS patients."

Multidisciplinary research team



ALS Nursing Care





care system for advanced amyotrophic lateral sclere

Chiharu Matsuda, Ph.D.

5010	pe	ALIX	21.1	
		2	4	州
11 22	1	100	-18	100

Variables	Odds ratio.	95% CI	Pivalue	
Age at beginning of TIV use, years	0.937	0.845-1.041	0.225	
Duration of TIV use, months	1 022	1.000-1.044	0.050	
ALSFRS-R score	0.822	0.314-2.146	0.314	
Body mass more, kgm/	1.653	1.150-2.370	0.007	
Energy Wtake, koalid	1.001	0.995-1.008	0.784	
Stages of communication	\$771	1 150-12 370	0.079	

Contraction in the second s	Year		The second second second second	Dat
Canadyte	2008	2012	p-ske	Pat
Spenterie ALB with MV (H)	242	328	- Contractor	
Men / Woman (n)	184.008	1747918	0.052	
Age (years)	06-0 x 11.1	0574154	0.541	
Age at crisit (years)	80.8 ± 12.8	50.2 ± 13.8	0.358	14
Duration from onset to diagnosis (years)	22140	0.7 ± 1.1	0.00-17	5 II M
Duator from prest to the begroung of MV (years)	37143	36+23	0.003*	- TI (2
NV (n)		-10	+0.009*	• 11 B
TM 00	21	.270	0.432	 III (1997)
Changes from NAV to TWV (n)	68	25	COMP.C.	and the second second
Duration of THY was (anothe)	1 N+ 1899 42.7 s 45.0	0+3430 83.7 ± 49.8	+0.001*	-111/10
Dustion of MN site (months)	(n+3) 103±70	(m-27) 25.0 ± 30.5	6.307	

ients with Intractable Diseases Analyze their physical and psycho-social Data Yumi Itagaki, M.S.



ALS Nursing



Nakamura S*, Oba M*, Suzuki M, Takahashi A, Yamamuro T, Fujiwara M, Ikenaka K, Minami S, Tabata N, Yamamoto K, Kubo S, Tokumura A, Akamatsu K, Miyazaki Y, Kawabata T, Hamasaki M, Fukui K, Sango K, Watanabe Y, Takabatake Y, Kitajima TS, Okada Y, Mochizuki H, Isaka Y, Antebi A, and Yoshimori T. (2019) "Suppression of autophagic activity by Rubicon is a signature of aging." *Nat. Commun.* 10:847 (*First authors)

Takaku S, Yako H, Niimi N, Akamine T, Kawanami D, Utsunomiya K, and Sango K. (2018) "Establishment of a myelinating co-culture system with a motor neuron-like cell line NSC-34 and an adult rat Schwann cell line IFRS1." *Histochem. Cell Biol.* 149:537-543.

Yoshida S, Hasegawa T, Suzuki M, Sugeno N, Kobayashi J, Ueyama M, Fukuda M, Ido-Fujibayashi A, Sekiguchi K, Ezura M, Kikuchi A, Baba T, Takeda A, Mochizuki H, Nagai Y, and Aoki M. (2018) "Parkinson's disease-linked DNAJC13 mutation aggravates alpha-synuclein-induced neurotoxicity through perturbation of endosomal trafficking." *Hum. Mol. Genet.* 27:823-836.

Niimi N, Yako H, Takaku S, Kato H, Matsumoto T, Nishito Y, Watabe K, Ogasawara S, Mizukami H, Yagihashi S, Chung SK, and Sango K. (2018) "A spontaneously immortalized Schwann cell line from aldose reductasedeficient mice as a useful tool for studying polyol pathway and aldehyde metabolism." *J. Neurochem.* 144:710-722.

Sango K, Mizukami H, Horie H, and Yagihashi S. (2017) "Impaired axonal regeneration in diabetes. Perspective on the underlying mechanism from in vivo and in vitro experimental studies." *Front. Endocrinol.* 8:12.

abetic Neuropat

Project Leader Kazunori Sango Diabetic Neuropathy Project

Pathogenesis-based Therapeutic Approaches to Diabetic Neuropathy

One of the most common complications of Diabetes Mellitus, and its symptoms such as pain and numbness can be the cause of insomnia and depression. When allowed to progress to more advanced disease stages, peripheral neuropathy can result in serious consequences such as lower limb amputation and lethal arrhythmia. In addition, recent studies have indicated that diabetes is a major risk factor for cognitive disorders such as Alzheimer's disease.



"We are trying to improve QOL for diabetics and help them to live longer lives by elucidating the pathogenesis of neurological disorders and establishing effective treatments."





The goals of our project are as follows:

- 1) Establishing effective pathogenesis-based treatments for diabetic peripheral neuropathy.
- 2) Elucidating mechanistic links between metabolic dysfunction and neurodegenerative diseases.



Project1: Therapeutic Approaches to Diabetic *Peripheral Neuropathy* [Sango, Yako, Niimi, Takaku, Akamine]

Metabolic disorders and vascular abnormalities caused by hyperglycemia appear to be closely related to the development and progression of diabetic peripheral neuropathy.

Using diabetic model animals and culture systems of adult rodent **dorsal root ganglion (DRG) neurons** and **immortalized Schwann cells**, we seek to establish effective pathogenesis-based treatments for peripheral neuropathy.



Immortalized mouse Schwann cells IMS32

Project2: Mechanistic link between *Metabolic dysfunction* and *Neurodegenerative* Diseases [Suzuki, Oba]

Neurodegenerative diseases are considered to share a common molecular pathogenesis involving protein misfolding and aggregation. Recently, increasing evidence suggests a relationship between metabolic syndrome and Alzheimer's disease. By using a **Drosophila model**, we aim to understand the molecular mechanism by which metabolic conditions influence misfolding protein-induced neurodegeneration.



Diabetic Neuropathy